Objectives: Test and compare the possible cardio-protective effects of AT1 blockade, ACEi, PPAR gamma activation and antioxidant therapy in type 2 diabetic hearts, through the modulation of the expression of cardiac AT2 receptor and ACE2. Methods: A total of 126 male albino rats were used in this study weighting 160-180 grams. The animals were housed in wire mesh cages at room temperature, with normal light dark cycle. They were fed the commercial rat chew diet and had free access to water. These rats were divided into the following groups: Group 1: Control group ,Group 2: Type2 diabetic rats, Group 3: A RB-protected type2 diabetic rats group, Group 4: ACEi- protected type2 diabetic rats group, Group 5: PPARγ agonist protected type2 diabetic rats group, Group 6: Antioxidant protected type2 diabetic rats group and Group 7: Metformin treated type2 diabetic rats group. Half the number of each group was sacrificed and the heart excised and perused according to the Langendorff technique, from the rest of the group small piece from the heart was taken for estimation of AT2R and ACE2 expression and malondialdehyde (MDA). Results: Treatment with ARB and ACEi reduces the FBS and insulin resistant and oxidative stress in type 2 diabetes and improve myocardial percentage recovery following ischemia reperfusion more than ordinary antioxidant drugs and this is related to increase expression of AT2 receptors and ACE2. Conclusion: The use of ARB and ACEi in the treatment of heart disease with type 2 diabetes significantly offered cardioprotection and improved the diabetic condition and may postpone the onset of diabetes in predisposed person.